Novel substituted pteridine-derived inhibitors of monocarboxylate transporter 1 (MCT1), an emerging target for cancer therapy, are reported. The activity of these compounds as inhibitors of lactate transport was confirmed using a 14C-lactate transport assay, and their potency against MCT1-expressing human tumor cells was established using MTT assays. The four most potent compounds showed substantial anticancer activity (EC50 37–150 nM) vs MCT1-expressing human Raji lymphoma cells.
A general synthetic approach to β-carboline-containing alkaloids was developed. Two consecutive palladium-mediated processes, a Sonagashira coupling and a Larock indole annulation reaction, are central to the method. The scope of the approach was investigated and found to be amenable for constructing a variety of biologically significant natural products and also for preparing substituted analogues for optimization and analysis of their biological properties.
24 November 2021 in Proceedings of the National Academy of Sciences
Significance: Analgesic tolerance can result upon chronic use of opioid drugs necessitating dose escalation to treat pain. The biased mu opioid receptor agonist SR-17018 maintains antinociceptive efficacy without evidence of tolerance when given chronically to mice. Here, we show that SR-17018 and related compounds are noncompetitive agonists that stabilize the receptor in an active state that can still be blocked by orthosteric antagonists. We propose that this mode of activation may contribute to the biased agonists’ apparent ability to preferentially induce G protein signaling in cellular assays and may underlie the enduring efficacy observed for SR-17018 in vivo.